NCT00387322View on ClinicalTrials.gov

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

May 31, 2009

Conditions
Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

erlotinib hydrochloride

Given orally

DRUG

pemetrexed disodium

Given IV

Trial Locations (1)

95817

University of California Davis Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Davis

OTHER

NCT00387322 - Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | Biotech Hunter | Biotech Hunter